If the U.S.-Canada trade war starts to impact drug prices, pharmacists will need tools to respond—and the government should be prepared to provide relevant financials supports, argues Shelita Dattani.
Insisting on primary birth sex identification for trans people does little to improve the health of trans and gender diverse persons; it merely exchanges one theoretical set of adverse health care outcomes for others that are definite and far more impactful.